ArticleJournal of orthopaedic surgery and research2025
The efficacy of oxidised regenerated cellulose powder in reducing blood loss during primary total hip arthroplasty: a retrospective cohort study.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Risk prediction models for blood transfusion in patients undergoing total hip and knee arthroplasty: a systematic review and meta-analysis.Annals of medicine · 2026Pooled it
- Efficacy and Outcomes of Oxidized Regenerated Cellulose (ORC) in Total Joint Arthroplasty (TJA): A Systematic Review and Meta-Analysis.The Iowa orthopaedic journal · 2026Pooled it
- Effectiveness and Safety of Oxidized Regenerated Cellulose for Hemostasis in Joint Arthroplasty: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Topical oxidized regenerated cellulose for perioperative blood management in total hip and knee arthroplasty: a systematic review and meta-analysis.Frontiers in surgery · 2026Article
- Hypertension and grading are important risk factors for occult blood loss in hip arthroplasty: a retrospective study analysis.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOxidised regenerative cellulose (ORC) is an absorbable haemostatic agent that acts independently on the blood coagulation mechanisms. Although ORC products have been used as adjuncts in various surgical procedures, their haemostatic effect, particularly the powder type (Surgicel
methodsThis study included 279 patients who underwent primary THA between January 2022 and July 2024, and they were divided into two groups based on the use of ORC powder: the control (n = 138) and SC (SurgiCel group, n = 141) groups. Data on perioperative outcomes, including operative time, total blood loss (TBL), intraoperative blood loss (IBL), hidden blood loss (HBL), haemoglobin (Hb) drops, and complication rates over 3 months, were collected and compared between the two groups.
resultsThe mean IBL was significantly lower in the SC group (197.1 mL) than in the control group (243.5 mL) (P < 0.001). The total operative time (P = 0.465), procedure time (P = 0.117), TBL (P = 0.167), and HBL (P = 0.771) showed no significant differences. The mean postoperative Hb drop was significantly different between the control and SC groups (1.5 vs. 1.0 g/dL, P < 0.001). Similarly, the mean postoperative day 1 Hb drop was significantly lower in the SC group than in the control group (1.7 vs. 2.0 g/dL, P = 0.013). Complication rates showed no significant differences during the 3-month postoperative follow-up.
conclusionsORC powder significantly reduced IBL and postoperative Hb drops without any comparable complications in patients undergoing primary THA. These findings suggest that ORC powder is a safe and effective haemostatic agent during primary THA procedures, which may be a valuable adjuvant for reducing blood loss and potential to reduce blood transfusion requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.